

## DAFTAR PUSTAKA

- A. Randale, A. and N Parate, S. (2020) 'Nottingham Prognostic Index: Useful tool to assess outcome inpatients of breast carcinoma', *IP Archives of Cytology and Histopathology Research*, 5(1), pp. 9–13. doi: 10.18231/j.achr.2020.003.
- Alkabban, F. M. and Ferguson, T. (2021) *Breast Cancer, StatPearls*. Treasure Island (FL): StatPearls Publishing.
- Alkabban FM, Ferguson T. Breast Cancer. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
- Arima, N. *et al.* (2016) 'The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index', *Journal of Clinical Pathology*, 69(3). doi: 10.1136/jclinpath-2015-203174.
- Bistoni, G. and Jian, F. (2015) 'Anatomy and physiology of the breast', in Farhadieh, R. D., Bulstrode, N. W., and Cugno., S. (eds) *Plastic and Reconstructive Surgery: Approaches and Techniques*. 5th edn. London: John Wiley & Sons, Ltd. Published. doi: 10.1002/9781118655412.ch37.
- Cheang MC, Chia SK, Voduc D, et al. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst*. 2009;101(10):736–50.
- Combs, S. E. *et al.* (2016) 'Loss of antigenicity with tissue age in breast cancer', *Laboratory Investigation*, 96(3). doi: 10.1038/labinvest.2015.138.
- Ellis, H. and Mahadevan, V. (2013) 'Anatomy and physiology of the breast', *Surgery (United Kingdom)*, 31(1), pp. 11–14. doi: 10.1016/j.mpsur.2012.10.018.
- Fong, Y. *et al.* (2015) 'The Nottingham Prognostic Index: Five- and ten-year data for all-cause survival within a screened population', *Annals of the Royal College of Surgeons of England*, 97(2), pp. 137–139. doi: 10.1308/003588414X14055925060514.
- Goldhirsch, A. *et al.* (2013) 'Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013', *Annals of Oncology*, 24(9). doi: 10.1093/annonc/mdt303.
- Gourgou-Bourgade, S. *et al.* (2015) 'Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-

- to-event Endpoints in CANcer trials)', *Annals of Oncology*, 26(5), pp. 873–879. doi: 10.1093/annonc/mdv106.
- Gray, E. *et al.* (2018) 'Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: A systematic review and meta-analysis of observational studies', *Systematic Reviews*, 7(1), pp. 1–9. doi: 10.1186/s13643-018-0803-9.
- Green, A. R. *et al.* (2016) 'Nottingham prognostic index plus: Validation of a clinical decision making tool in breast cancer in an independent series', *Journal of Pathology: Clinical Research*, 2(1), pp. 32–40. doi: 10.1002/cjp2.32.
- Green AR, Soria D, Powe DG, Nolan CC, Aleskandarany M, Szász MA, Tőkés AM, Ball GR, Garibaldi JM, Rakha EA, Kulka J, Ellis IO. Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. *Breast Cancer Res Treat.* 2016 May;157(1):65-75. doi: 10.1007/s10549-016-3804-1. Epub 2016 Apr 26. Erratum in: *Breast Cancer Res Treat.* 2016 Aug;159(1):199.
- Hamdi, M. *et al.* (2005) 'Anatomy of the breast: A clinical application', *Vertical Scar Mammoplasty*, pp. 1–8. doi: 10.1007/3-540-27218-6\_1.
- Harbeck, N. *et al.* (2019) 'Breast cancer', *Nature Reviews Disease Primers*, 5(1). doi: 10.1038/s41572-019-0111-2.
- Hortobagyi, G. N. *et al.* (2018) 'Breast', in Amin, M. B. (ed.) *AJCC Cancer Staging Manual*,. 8th edn. American College of Surgeons. doi: 10.1002/jso.2930040408.
- Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. *Breast Cancer (Auckl)*. 2013;7:23-34. doi: 10.4137/BCBCR.S10701. Epub 2013 Feb 13.
- Al jarroudi, O. *et al.* (2019) 'Nottingham prognostic index is an applicable prognostic tool in non-metastatic triple-negative breast cancer', *Asian Pacific Journal of Cancer Prevention*, 20(1), pp. 59–63. doi: 10.31557/APJCP.2019.20.1.59.
- Kabel, A. M. and Baali, F. H. (2015) 'Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management', *Journal of Cancer Research and Treatment*, 3(2), pp. 28–33. doi: 10.12691/jcrt-3-2-3.
- Karihtala, P. *et al.* (2020) 'Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital', *BMJ Open*, 10(10), pp. 1–6. doi:

- Khambri, D. *et al.* (2016) ‘Pentingnya Pemeriksaan Androgen Reseptor (AR) Terhadap Penderita Karsinoma Payudara di Sumatera Barat’, ..., 6(2).
- Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013;108(11):2205–40.
- Momenimovahed, Z. and Salehiniya, H. (2019) ‘Epidemiological characteristics of and risk factors for breast cancer in the world’, *Breast Cancer: Targets and Therapy*, 11, pp. 151–164. doi: 10.2147/BCTT.S176070.
- National Comprehensive Cancer Network (2020) *NCCN Clinical Practice Guidelines in Oncology: Breast Cancer*.
- Panigroro, S., Hernowo, B. S. and Purwanto, H. (2019) ‘Panduan Penatalaksanaan Kanker Payudara (Breast Cancer Treatment Guideline)’, *Jurnal Kesehatan Masyarakat*, 4(4), pp. 1–50.
- Parker, J. S. *et al.* Supervised risk predictor of breast cancer based on intrinsic subtypes. *J. Clin. Oncol.* **27**, 1160–1167 (2009).
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005;55:74–108.
- Phung, M. T., Tin Tin, S. and Elwood, J. M. (2019) ‘Prognostic models for breast cancer: A systematic review’, *BMC Cancer*, 19(1), pp. 1–18. doi: 10.1186/s12885-019-5442-6.
- Ramli, M. (2015) ‘Update Breast Cancer Management’, *Jurnal Fakultas Kedokteran Andalas*, 38.
- Sejben A., Nyári T., Zombori T., Cserni G. Comparison of nottingham prognostic index, predict and prognostils in triple negative breast cancer—a retrospective cohort study. *Pathol. Oncol. Res.* 2020;26:2443–2450. doi: 10.1007/s12253-020-00846-8.
- Shah, R., Rosso, K. and David Nathanson, S. (2014) ‘Pathogenesis, prevention, diagnosis and treatment of breast cancer’, *World Journal of Clinical Oncology*, 5(3), pp. 283–298. doi: 10.5306/wjco.v5.i3.283.
- Siregar, K. B. (2013) ‘Profil ekspresi HER2 dan Ki67 pada berbagai kelompok usia penderita kanker payudara di RSUP H. Adam Malik Medan’, *Majalah Kedokteran Nusantara The Journal Of Medical School*, 46(3).
- Tortora, G. J. and Derrickson, B. (2012) *Principles of Anatomy & Physiology*. 13th edn. New

Jersey: Wiley.

Winzer, K. J. *et al.* (2016) 'Improving the prognostic ability through better use of standard clinical data - the nottingham prognostic index as an example', *PLoS ONE*, 11(3). doi: 10.1371/journal.pone.0149977.

World Health Organization (2021) *Breast Cancer, Fact Sheet*.

Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. *J Breast Cancer*. 2012 Jun;15(2):203-10. doi: 10.4048/jbc.2012.15.2.203. Epub 2012 Jun 28.